Technical Snapshots for These Drug Makers Stocks -- SciClone Pharma, Synergy Pharma, Novo Nordisk, and United Therapeutics

Tuesday, October 17, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, October 17, 2017 /PRNewswire/ --

If you want a Stock Review on SCLN, SGYP, NVO, or UTHR then come over

to and sign up for your free customized report. Today's investors' attention is directed to the Drug Manufacturers space, which consists of establishments primarily engaged in one or more of the following: manufacturing
biological and medical products; processing botanical drugs and herbs; isolating active medical principles from botanical drugs and herbs; and manufacturing pharmaceutical products intended for internal and external consumption in such forms as tablets, capsules, ointments, powders, and solutions. Pre-market this morning, recalls the recent performance of SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), and United Therapeutics Corp. (NASDAQ: UTHR). Access's complimentary reports for today's stocks line-up at:

SciClone Pharmaceuticals 

Shares in Foster City, California headquartered SciClone Pharmaceuticals Inc. ended Monday's trading session flat at $11.15. The stock recorded a three months average volume of 483,660 shares. The Company's shares have gained 0.45% in the last one month, 1.36% over the last three months, and 3.24% on an YTD basis. The stock is trading 0.59% and 7.36% above its 50-day and 200-day moving averages, respectively. Moreover, shares of SciClone Pharma have a Relative Strength Index (RSI) of 54.94.

On October 13th, 2017, SciClone Pharma ("SCLN") and a consortium consisting of entities affiliated with GL Capital Management GP Limited; Bank of China Group Investment Limited; CDH Investments; Ascendent Capital Partners; and Boying announced completion of the merger contemplated by the previously announced agreement and plan of merger dated June 07th, 2017, by and between Silver Biotech Investment Limited ("Holdco"); Silver Delaware Investment Limited; and SCLN. As a result of the merger, SCLN ceased to be a publicly traded company on the NASDAQ Global Select Market, and became a subsidiary of Holdco. Visit us today and access your complete report on SCLN for free at:

Synergy Pharmaceuticals 

New York headquartered Synergy Pharmaceuticals Inc.'s stock declined 1.62%, closing the day at $3.04. A total volume of 5.47 million shares was traded, which was above their three months average volume of 4.93 million shares. The Company's shares have advanced 12.59% in the past month. The stock is trading 0.99% above its 50-day moving average. Additionally, shares of Synergy Pharma have an RSI of 49.89.  

On September 25th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $15 a share to $8 a share.

On October 12th, 2017, Synergy Pharma announced that it will present two abstracts, including Phase-3 studies evaluating TRULANCE® (plecanatide) for the treatment of adults with irritable bowel syndrome with constipation at the World Congress of Gastroenterology at American College of Gastroenterology in Orlando, Florida. The data will be presented via poster presentations on October 17th, 2017, beginning 1:15 p.m. to 2:30 p.m. ET. The complimentary research report on SGYP can be accessed at:

Novo Nordisk 

On Monday, shares in Bagsvaerd, Denmark headquartered Novo Nordisk A/S recorded a trading volume of 3.33 million shares, which was higher than their three months average volume of 1.94 million shares. The stock ended the day 3.77% higher at $49.32. The Company's shares have advanced 2.34% in the past month, 14.19% in the previous three months, and 37.53% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.49% and 21.64%, respectively. Furthermore, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 57.11.

On September 25th, 2017, research firm Exane BNP Paribas downgraded the Company's stock rating from 'Outperform' to 'Neutral'.

On October 03rd, 2017, Novo Nordisk announced the availability of Tresiba® (insulin degludec injection) in Canada, a new basal insulin for the once-daily treatment of adults with diabetes mellitus to improve glycemic control. Unlike other basal insulins in Canada, Tresiba® provides a duration of action beyond 42 hours with a flat and stable glucose-lowering effect. Register for free on and download the research report on NVO at:

United Therapeutics 

Silver Spring, Maryland headquartered United Therapeutics Corp.'s stock declined 0.61%, finishing yesterday's session at $119.78 with a total trading volume of 301,811 shares. The Company's shares are trading below their 50-day moving average by 4.50%. The stock has an RSI of 43.48.

On September 19th, 2017, United Therapeutics Chairman and CEO Martine Rothblatt was featured in Forbes magazine's special centennial issue, released that day, as one of The World's 100 Greatest Living Business Minds. In celebration of its 100th anniversary, the magazine's collector's edition featured essays, lessons, and ideas for the next 100 years from today's most influential business leaders around the world. Get free access to your research report on UTHR at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store